Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
31°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Tarsus Pharmaceuticals, Inc
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
November 13, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
November 13, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
November 06, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
November 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
October 17, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
September 25, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
August 28, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
August 08, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate in Upcoming Investor Conferences
May 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 09, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 08, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 23, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate at Upcoming Investor Conferences
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Pricing of $100.0 Million Public Offering
March 01, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Proposed $100.0 Million Public Offering
February 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
February 27, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
February 22, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
February 20, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
January 31, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
December 11, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
November 09, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
November 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
September 06, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Present at Upcoming Investor Conferences
August 30, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
August 24, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
August 10, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
August 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.